Kacital (Potassium Citrate)

Potassium citrate dissociates after oral intake, delivering potassium ions that replenish extracellular potassium and citrate anions that are metabolized to bicarbonate. The resulting increase in systemic and urinary pH reduces calcium oxalate supersaturation and helps correct acid‑base imbalances.

The appropriate dose of Kacital is determined by the prescribing healthcare professional based on the patient’s serum potassium level, renal function, and the specific indication being treated. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for potassium citrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Kacital, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both potassium citrate and sodium bicarbonate alkalinize urine, but potassium citrate also supplies potassium, making it suitable for patients who need potassium repletion. Sodium bicarbonate does not provide potassium and may increase sodium load, which can be undesirable in certain cardiovascular conditions.

Kacital should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Kacital is taken orally, usually as a solution or tablet, according to the prescriber’s directions. It may be taken with or without food, but patients should follow any specific instructions regarding timing or fluid intake provided by their healthcare professional.

The most serious risks include hyperkalemia, which can cause cardiac arrhythmias, and metabolic alkalosis, which may lead to neuromuscular symptoms. Rarely, severe allergic reactions such as anaphylaxis can occur. Patients should seek immediate medical attention if they experience symptoms of these conditions.

Kacital should be avoided in patients with known hypersensitivity to potassium citrate, those with severe renal impairment where potassium excretion is compromised, and individuals with existing hyperkalemia or metabolic alkalosis unless closely monitored by a physician.